FHD-609

About Foghorn Therapeutics

Foghorn Therapeutics is a clinical-stage biotechnology company developing novel therapeutics targeting the chromatin regulatory system, a key driver in over half of all cancers. Its mission is to create precision medicines by selectively modulating chromatin remodeling complexes, such as the BAF complex, to address genetically determined dependencies in diseased cells. The company's strategy is powered by its integrated Gene Traffic Control® platform, which enables target identification, validation, and drug discovery at scale. Foghorn has advanced multiple candidates into Phase 1 trials and maintains a strategic collaboration with Loxo Oncology at Lilly, positioning it at the forefront of chromatin-based drug discovery.

Therapeutic Areas